vimarsana.com

Page 11 - அமெரிக்கன் சமூகம் க்கு கதிர்வீச்சு புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress

NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion. First clinical data reported phase I immuno-oncology trial showing conversion of anti-PD-1 non-responders to responders. Extended global capital markets presence with a successful Nasdaq IPO that provided gross proceeds of €93.5 million ($113.3 million). Cash, cash equivalents, and short-term investments were €119.2 million at December 31, 2020, supporting robust development plans into the second quarter of 2023.

AHN Cancer Institute Opens Genomics Facility Offering Patients Next-Generation Gene Sequencing to Guide Treatment Decisions

AHN Cancer Institute Opens Genomics Facility Offering Patients Next-Generation Gene Sequencing to Guide Treatment Decisions Share Article Pittsburgh-based Allegheny Health Network (AHN) Cancer Institute has opened a new Clinical Genomics Laboratory, offering comprehensive, advanced, in-house genomic testing that guides doctors in selecting treatments to give cancer patients their best chance at a good outcome. William LaFramboise, PhD, Chief Genomics Technology Officer, Allegheny Health Network, and David Bartlett, MD, Chair, AHN Cancer Institute, in AHN s new Clinical Genomics Laboratory We believe that offering on-site genomic testing offers a number of advantages to our patients, including a quicker turnaround time and better stewardship of our patients’ samples. - David L. Bartlett, MD, Chair, AHN Cancer Institute

The Impact of COVID-19 on Oncology Pharmacy and Patient Care, Part 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.